GS-9450 is an effective caspase inhibitor for caspases 1,8, and 9 and has been explored for NASH in a randomized, double-blind, placebo-controlled study, which demonstrated the potent effect in decreasing ALT levels safely and with tolerance. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.